Faded Genes

Slow start for bioengineering

Like a highly touted rookie who does nothing but strike out once the baseball season begins, genetic-engineering companies are having trouble living up to their early billing. A year ago, they were among the hottest companies on Wall Street. Stock in Genentech, the first of the leading firms to offer its shares to the public, jumped from $35 to $89 during the opening few minutes of trading in October 1980.

Many of the wonder-drug companies, though, are not finding easy profits in their test tubes. In February, Bethesda Research Laboratories, of...

Want the full story?

Subscribe Now


Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!